Maries Liana, Moatar Alexandra Ioana, Sala-Cirtog Maria, Sima Laurentiu, Anghel Andrei, Marian Catalin, Chis Aimee Rodica, Sirbu Ioan-Ovidiu
Biochemistry Department, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Doctoral School, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Biomedicines. 2023 Oct 10;11(10):2738. doi: 10.3390/biomedicines11102738.
Left ventricle remodeling (LVR) after acute myocardial infarction (MI) leads to impairment of both systolic and diastolic function, a significant contributor to heart failure (HF). Despite extensive research in the field, predicting post-MI LVR and HF is still a challenge. Several circulant microRNAs have been proposed as LVR predictors; however, their clinical value is controversial. Here, we used real-time quantitative PCR to quantify the plasma levels of hsa-miR-101, hsa-miR-150, and hsa-miR-21 on the first day of hospital admission of MI patients with ST-elevation (STEMI). We analyzed their correlation to the patient's clinical and paraclinical variables and evaluated their ability to discriminate between post-MI LVR and non-LVR. We show that, despite being excellent MI discriminators, none of these microRNAs can distinguish between LVR and non-LVR patients. Furthermore, we found that diabetes mellitus (DM), Hb level, and the number of erythrocytes significantly influence all three plasma microRNA levels. This suggests that plasma microRNAs' diagnostic and prognostic value in STEMI patients should be reevaluated and interpreted in the context of associated pathologies.
急性心肌梗死（MI）后的左心室重构（LVR）会导致收缩和舒张功能受损，这是心力衰竭（HF）的一个重要促成因素。尽管该领域已有广泛研究，但预测心肌梗死后的左心室重构和心力衰竭仍然是一项挑战。几种循环微小RNA已被提议作为左心室重构的预测指标；然而，它们的临床价值存在争议。在此，我们使用实时定量聚合酶链反应来定量ST段抬高型心肌梗死（STEMI）患者入院第一天时血浆中hsa-miR-101、hsa-miR-150和hsa-miR-21的水平。我们分析了它们与患者临床和副临床变量的相关性，并评估了它们区分心肌梗死后左心室重构和非左心室重构的能力。我们发现，尽管这些微小RNA都是优秀的心肌梗死判别指标，但没有一种能区分左心室重构和非左心室重构患者。此外，我们发现糖尿病（DM）、血红蛋白水平和红细胞数量会显著影响所有三种血浆微小RNA水平。这表明，STEMI患者血浆微小RNA的诊断和预后价值应在相关病理背景下重新评估和解读。
